An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid

Trial Profile

An Open Label Phase II Multiple Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 Followed by Open Label Administration of SEL-037 in Subjects With Symptomatic Gout and Elevated Blood Uric Acid

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs Pegadricase (Primary) ; SEL 212 (Primary) ; Sirolimus (Primary)
  • Indications Gout
  • Focus Adverse reactions
  • Sponsors Selecta Biosciences
  • Most Recent Events

    • 13 Nov 2017 According to a Selecta Biosciences media release, updates from the study will be presented at Jefferies 2017 London Healthcare Conference.
    • 08 Nov 2017 Results (n=60; as of 12 Jun 2017) presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
    • 07 Nov 2017 According to a Selecta Biosciences media release, the company plans to present additional data from this trial at a medical meeting in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top